Aflac (AFL) FY2025 10-K Annual Report
Aflac (AFL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Aflac FY2025 10-K Analysis
Business Overview
- • Supplemental health and life insurer operating dual-segment model: Aflac Japan (largest cancer/medical insurer in Japan) and Aflac U.S. worksite benefits
- • Two new Japan product launches: cancer insurance "Miraito" (March 2025) and medical insurance "Anshin Palette" (December 2025), both featuring modular, customer-configurable coverage
Management Discussion & Analysis
- • Total revenues $17.2B, down 9.3% YoY from $18.9B; decline driven by net investment losses of $572M vs gains of $1.3B in 2024
- • Net earnings $3.6B ($6.82/share) vs $5.4B ($9.63/share) in 2024; adjusted earnings $4.0B ($7.49/share) vs $4.1B ($7.21/share); Aflac U.S. pretax adjusted margin 20.6% vs 21.1%; Aflac Japan pretax adjusted margin 36.7% vs 36.0%
Risk Factors
- • Japan concentration: Aflac Japan = 53% of adjusted revenues and 76% of total assets in 2025, with substantial JGB holdings exposed to sovereign credit risk
- • Yen/dollar FX risk: Aflac Japan liabilities yen-denominated but portfolio includes unhedged USD assets; rising US-Japan rate differential increases hedging costs materially
Aflac FY2025 Key Financial MetricsXBRL
Revenue
$17.2B
▼ -9.3% YoY
Net Income
$3.6B
▼ -33.0% YoY
Net Margin
21.2%
▼ -752bp YoY
ROE
12.4%
▼ -849bp YoY
Total Assets
$116.5B
▼ -0.9% YoY
EPS (Diluted)
$6.82
▼ -29.2% YoY
Operating Cash Flow
$2.6B
▼ -5.6% YoY
Source: XBRL data from Aflac FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Aflac Annual Reports
Get deeper insights on Aflac
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.